| Company Name: | Abbott Laboratories | | Ticker Symbol: | ABT | | | WWW Address: | www.abbott.com | | CEO: | Miles D. White | | No. of Employees: | 69,000 | | Common Issue Type: | CS | | Business Description: | The Company is engaged in the discovery, development, manufacture and sale of a line of health care products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 53.64 |  0.68 | 52.61 | 53.94 | 53.25 | 53.74 | 52.84 | 6045246 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 82,965.0 | 1,546.7 | 0.19 | 3.12 | 1.41 | 14.6 | 3.0 | 57.39 - 41.27 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 53.64 | $ | | PE Ratio - LTM | 14.6 | |
| Market Capitalisation | 82,967.0 | mil |
| Latest Shares Outstanding | 1,546.7 | mil |
| Earnings pS (EPS) | 3.12 | $ |
| Dividend pS (DPS) | 1.41 | ¢ |
| Dividend Yield | 3.0 | % |
| Dividend Payout Ratio | 45 | % |
| Revenue per Employee | 427,936 | $ |
| Effective Tax Rate | 19.2 | % |
| Float | 1,541.9 | mil |
| Float as % of Shares Outstanding | 99.7 | % |
| Foreign Sales | 15,033 | mil |
| Domestic Sales | 14,495 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 9.10 | % |
| Gross Profit Margin | 64.4 | % |
| EBITDA Margin | 27.0 | % |
| Pre-Tax Profit Margin | 23.6 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 11.5 | % |
| Return on Equity (ROE) | 26.9 | % |
| Return on Capital Invested (ROCI) | 17.5 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 2.3 | |
| Interest Cover | 14.6 | |
| Total Debt/Equity (Gearing Ratio) | 0.73 | |
| LT Debt/Total Capital | 35.0 | % |
| Working Capital pS | 5.75 | $ |
| Cash pS | 3.15 | $ |
| Book-Value pS | 13.79 | $ |
| Tangible Book-Value pS | 1.86 | $ |
| Cash Flow pS | 4.98 | $ |
| Free Cash Flow pS | 1.16 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.89 | |
| Price/Tangible Book Ratio | 28.78 | |
| Price/Cash Flow | 10.8 | |
| Price/Free Cash Flow | 46.3 | |
| P/E as % of Industry Group | 66.0 | % |
| P/E as % of Sector Segment | 86.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 09/17/2009 |
| Dividend Ex-Date | 10/12/2009 |
| Dividend Record Date | 10/14/2009 |
| Dividend Pay Date | 11/14/2009 |
| Dividend Amount | 400 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.60 |
| Current Dividend Yield | 3.0 |
| 5-Y Average Dividend Yield | 2.5 |
| Payout Ratio | 45.0 |
| 5-Y Average Payout Ratio | 61.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.3 | 101 | 57,772 | 302,318 |
| 4 Weeks | 53.89 | 50.07 | 51.31 | 4.5 | 103 | 57,279 | 1,145,582 |
| 13 Weeks | 53.89 | 44.72 | 45.39 | 18.2 | 111 | 77,371 | 4,951,719 |
| 26 Weeks | 53.89 | 43.45 | 43.94 | 22.1 | 99 | 82,365 | 10,460,322 |
| 52 Weeks | 57.39 | 41.27 | 51.52 | 4.1 | 76 | 93,000 | 23,343,013 |
| YTD | 57.39 | 41.27 | - | 0.5 | 83 | 95,036 | 21,383,171 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 53.34 | 53.13 | 50.35 | 46.85 | 47.12 | 0.19 | 0.23 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 8.80 | 93.9 | 10.02 |
| Income | 12.02 | 30.6 | 36.96 |
| Dividend | 8.01 | 97.8 | 8.81 |
| Capital Spending | -3.25 | NA | -15.23 |
| R&D | 10.74 | NA | 8.63 |
| Normalized Inc. | 9.26 | NA | 14.23 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 1.8 | 3.5 | 13.9 |
| Earnings % | 25.8 | 36.5 | 35.3 |
| EPS % | 26.2 | 37.7 | 35.1 |
| EPS $ | 0.56 | 0.26 | 0.81 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 12.85 |
| Current Ratio | 1.5 |
| Quick Ratio (Acid Test) | 0.9 |
| Liquidity Ratio (Cash) | 0.44 |
| Receivables Turnover | 5.7 |
| Average Collection Period | 63 |
| Working Capital/Equity | 31.2 |
| Working Capital pS | 3.53 |
| Cash-Flow pS | 4.35 |
| Free Cash-Flow pS | 2.35 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.57 |
| Financial Leverage Ratio (Assets/Equity) | 2.4 |
| Debt Ratio | 58.8 |
| Total Debt/Equity (Gearing Ratio) | 0.65 |
| LT Debt/Equity | 0.50 |
| LT Debt/Capital Invested | 51.0 |
| LT Debt/Total Liabilities | 34.9 |
| Interest Cover | 12.1 |
| Interest/Capital Invested | 1.71 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 13.96 |
| Tobin's Q Ratio | 1.96 |
| Current P/E Ratio - LTM | 14.60 |
| Enterprise Value (EV)/EBITDA | 13.48 |
| Enterprise Value (EV)/Free Cash Flow | 29.57 |
| Dividend Yield | 3.0 |
| Price/Tangible Book Ratio - LTM | 28.78 |
| Price/Book Ratio - LTM | 3.89 |
| Price/Cash Flow Ratio | 10.8 |
| Price/Free Cash Flow Ratio - LTM | 46.3 |
| Price/Sales Ratio | 2.77 |
| P/E Ratio (1 month ago) - LTM | 14.1 |
| P/E Ratio (26 weeks ago) - LTM | 12.8 |
| P/E Ratio (52 weeks ago) - LTM | 17.7 |
| 5-Y High P/E Ratio | 44.5 |
| 5-Y Low P/E Ratio | 14.7 |
| 5-Y Average P/E Ratio | 25.2 |
| Current P/E Ratio as % of 5-Y Average P/E | 58 |
| P/E as % of Industry Group | 66.0 |
| P/E as % of Sector Segment | 86.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 14.9 |
| PER SHARE FIGURES |
| LT Debt pS | 5.64 |
| Current Liabilities pS | 7.50 |
| Tangible Book Value pS - LTM | 1.86 |
| Book Value pS - LTM | 13.79 |
| Capital Invested pS | 16.93 |
| Cash pS - LTM | 3.15 |
| Cash Flow pS - LTM | 4.98 |
| Free Cash Flow pS - LTM | 1.16 |
| Earnings pS (EPS) | 3.12 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 12.30 |
| Free Cash Flow Margin 5YEAR AVG | -0.46 |
| Net Profit Margin | 16.5 |
| Net Profit Margin - 5YEAR AVRG. | 14.0 |
| Equity Productivity | 1.69 |
| Return on Equity (ROE) | 27.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 21.5 |
| Capital Invested Productivity | 1.13 |
| Return on Capital Invested (ROCI) | 18.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 14.9 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 11.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.5 |
| Gross Profit Margin | 64.4 |
| Gross Profit Margin - 5YEAR AVRG. | 62.1 |
| EBITDA Margin - LTM | 27.0 |
| EBIT Margin - LTM | 25.3 |
| Pre-Tax Profit Margin | 19.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 17.8 |
| Effective Tax Rate | 19.2 |
| Effective Tax Rate - 5YEAR AVRG. | 22.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 163 |
| Revenue per Employee | 427,936 |
| Net Income per Employee | 70,735 |
| Average Collection Period | 67 |
| Receivables Turnover | 5.7 |
| Day's Inventory Turnover Ratio | 96 |
| Inventory Turnover | 3.8 |
| Inventory/Sales | 9.4 |
| Accounts Payble/Sales | 4.58 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 5.42 |
| Fixed Assets Turnover | 1.16 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 7.18 |
| Revenue per $ Plant | 4.09 |
| Revenue per $ Common Equity | 1.69 |
| Revenue per $ Capital Invested | 1.13 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.2 |
| Research & Devlopment (R&D) as % of Revenue | 9.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 9.1 |
|
|  
| | |  |  | |
| |